Arbutus to Present at Jefferies London Healthcare Conference
08 November 2022 - 11:30PM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage
biopharmaceutical company leveraging its extensive virology
expertise to develop novel therapeutics that target specific viral
diseases, today announced that William Collier, Arbutus’ President
and Chief Executive Officer, will present at the Jefferies London
Healthcare Conference on Wednesday, November 16, 2022, at 11:30 am
GMT / 6:30 am EDT.
A live webcast of the presentation can be
accessed through the Investors section of Arbutus’ website at
www.arbutusbio.com. An archived replay of the webcast will be
available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV,
we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and
an oral RNA destabilizer that we intend to combine with the aim of
providing a functional cure for patients with chronic HBV by
suppressing viral replication, reducing surface antigen and
reawakening the immune system. We believe our lead compound,
AB-729, is the only RNAi therapeutic with evidence of immune
re-awakening. It is currently being evaluated in multiple phase 2
clinical trials. We also have an ongoing drug discovery and
development program directed to identifying novel, orally active
agents for treating coronavirus (including SARS-CoV-2). In
addition, we are exploring oncology applications for our internal
PD-L1 portfolio. For more information, visit
www.arbutusbio.com.Contact Information
Investors and Media
William H. CollierPresident and CEO Phone: 267-469-0914Email:
ir@arbutusbio.comLisa M. CaperelliVice President, Investor
RelationsPhone: 215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024